Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.
The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.
SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic ...
Illumina is launching a new informatics and artificial intelligence software business aimed at drug developers, with the goal of digesting large-scale DNA sequencing and multi-omics data. The ...
PORTLAND, Maine--(BUSINESS WIRE)--Ovation.io, Inc., an organization dedicated to building best in class multi-omics datasets, today announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), a ...
SAVANA uses a machine learning algorithm to identify cancer-specific structural variations and copy number aberrations in long-read DNA sequencing data. The complex structure of cancer genomes means ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback